NDA 017057 · Liebel-Flarsheim
Cysto-Conray Ii
Iothalamate Meglumine · Intravesical, Intravesical, Ureteral
Last checked: Nov 20, 2026Latest source record: Dec 19, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1972
Apr 17, 1972
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 0 recruiting
FAERS reports
16
5 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
NOT FOR INTRAVASCULAR ADMINISTRATION NOT FOR INTRATHECAL USE
What it is approved for
From the label in effect Dec 31, 2020.
INDICATIONS AND USAGE Cysto-Conray II is indicated for use in retrograde cystography and cystourethrography.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 17, 1972 Original approval · Type 3 - New Dosage Form
2 products under this application
- CYSTO-CONRAY II · IOTHALAMATE MEGLUMINE 17.2% · SOLUTION, INTRAVESICAL · Prescription
- CYSTO-CONRAY · IOTHALAMATE MEGLUMINE 43% · Solution, Intravesical, Ureteral · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Iothalamate Meglumine" as an intervention, any sponsor and status, largest first.
- Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration RateStatus unknown
University Medical Center GroningenAcademic, hospital or other
NCT06259422 · 208 participants (planned) · Start Jun 1, 2024 · Primary completion Sep 1, 2025
Drug: Iohexol · For: Kidney Function Issue; Diagnosis; Chronic Kidney Diseases
Sites: Groningen, Netherlands
Northwell HealthAcademic, hospital or other
NCT00193635 · 12 participants · Start Mar 2002
Drug: mycophenolate mofetil · For: Congenital Urological Abnormalities
Sites: New Brunswick, New Jersey; New Hyde Park, New York; New York, New York
- Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus ToxicityPivotal-lookingTerminated
University of PittsburghAcademic, hospital or other
NCT01709136 · 3 participants · Start Dec 2005 · Primary completion Jan 2010
Drug: Sirolimus · For: Hypertension
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- incorrect route of drug administration8
- wrong drug administered4
- anaphylactoid reaction2
- no adverse event2
- agranulocytosis1
- anaphylactic reaction1
- angioedema1
- cough1
- drug ineffective1
- expired product administered1
- fixed eruption1
- hypersensitivity1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Cysto-Conray Ii* (Iothalamate Meglumine*) · HCPCS Q9958
2024 spending
$9K
Beneficiaries
691
768 claims
Per beneficiary
$14
2024 ASP limit $0.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,981 |
| 2021 | $13,140 |
| 2022 | $10,356 |
| 2023 | $10,083 |
| 2024 | $9,453 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Assessment of a bolus-tracking technique in helical renal CT to optimize nephrographic phase imaging.
Birnbaum BA, Jacobs JE, Langlotz CP, et al. · Radiology 1999 · Clinical Trial, Randomized Controlled Trial
- Ascending lower limb phlebography: comparison of ioversol and iothalamate meglumine.
Wilson AJ, Murphy WA, Destouet JM, et al. · Can Assoc Radiol J 1989 · Clinical Trial, Comparative Study
- Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
Beringer PM, Kriengkauykiat J, Zhang X, et al. · Pharmacotherapy 2008 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Pregnancy rates after the use of oil-based and water-based contrast media to evaluate tubal patency.
Letterie GS, Rose GS · South Med J 1990 · Clinical Trial, Randomized Controlled Trial
- Comparison of helical and conventional computed tomography of the liver.
Bonaldi VM, Bret PM, Reinhold C, et al. · Can Assoc Radiol J 1995 · Clinical Trial, Comparative Study
- The use of iothalamate meglumine 17.2% as an effective testing medium in lower urinary tract urodynamic assessment of children.
Joseph DB · J Urol 1993 · Clinical Trial
Sponsor: Liebel-Flarsheim · Also marketed as Cysto-Conray
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.